nivolumabdegarelixpTVG-ARprostate cancerNCT04989946Arm 2Arm 3Arm 1
… Adverse events were almost exclusively in Arm 3, attributed to nivolumab. One patient achieved MRD (Arm 2), and three patients had an RC…
1articles mentioning drugs
3drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: degarelix ×
degarelix
This drug is selected. Its supporting articles are shown below.